Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Aktis Oncology, Inc.NASDAQ: AKTS
Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue (non-current) of $32.63M in Q1 FY2026
Q1 FY2026 deferred revenue (non-current) was $32.63M.
Context
- Deferred revenue (non-current) amounted to 5.7% of total assets at the end of Q1 FY2026.
- Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 36.16M USD
- Year-over-year change
- -29.2%
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.16M | -29.2% |
| FY2024 | 2024-12-31 | 51.04M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 deferred revenue (non-current) of $32.63M is the 2nd highest of the 6 companies compared; the peer median is $0.
- Deferred revenue (non-current) amounts to 5.7% of total assets for AKTS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $34.34M | -58.2% | -5.0% | 5.3% | |
| Mar 2026 | $32.63M | — | — | 5.7% | |
| Mar 2026 | $4.62M | -17.6% | -2.5% | 0.4% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -2.3% | 0.0% | |
| Peer median (excluding AKTS) | $0 | -58.2% | -2.5% | 0.0% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.